Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative ...

Several neuropsychiatric disorders such as attention deficit-hyperactivity disorder (ADHD), autism spectrum disorder (ASD), as well as neurological diseases such as spinocerebellar ataxia type 3 (SCA3 ...

Suggested remit: To appraise the clinical and cost effectiveness of Troriluzole within its marketing authorisation for treating ataxia.

Dalfampridine IR is under clinical development by Solaxa and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% ...

Eko Health, a leader in applying artificial intelligence (AI) for the early detection of heart and lung diseases, today ...

Recovery.com, a global platform that connects patients, loved ones, and providers to mental health and addiction treatment options, has released its first-ever State of Recovery report. Based on ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Turkish and European researchers will collaborate on the treatment of brain diseases and patient care through new projects ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

Friedreich ataxia, an autosomal recessive neurodegenerative disease, is the most common of the inherited ataxias. The recent discovery of the gene that is mutated in this condition,FRDA, has led to ...

Biohaven in December reported positive Phase I for an IgG-degrading treatment aimed at a variety of different autoimmune diseases, with other clinical trials on the backs of various treatments aimed ...